The Client:

Global Specialty Pharma

The Challenge:

The client needed to make decisions about the next steps in the development of a molecule for which the 1st indications were approved. The challenge was on the perceived level of uncertainty in the future environment and shortening time to loss of exclusivity of its own molecule. Investment decisions in this setting are fraught with questions of risk versus return and are often deferred.

The Process:

It was important to design a process for the opportunities to be assessed in a rigorous and objective manner that allowed clear risk-adjusted recommendations to be made to senior management.

The key stages included a deep research stage into each potential indication, both now and in the future followed by a number of interactive workshops with all the relevant internal cross-functional stakeholders involved.

Distillation of the outcomes into concise and clear recommendations that could be presented to the senior management group.

Key Outputs:

Clear recommendations were able to be made for the development of the asset which the senior management group felt could be supported and as such the fog of indecision was removed and the team was able to move forward.

Output Summary:

Multiple opportunities were evaluated by a cross-functional team through processes Osprey Health Consulting developed specifically for the purpose. Senior management was able to support the development recommendations and the resultant next steps.